Company intelligence / Profile preview

Allianz Pharmascience Ltd

Ownership: Private
Development stage: Phase 2

Overview

Allianz Pharmascience developed first-in-class small molecule drugs targeting neurodegeneration and dermatology indications. Its lead programs reached Phase 2 clinical trials before the company was acquired by AnnJi Pharmaceutical in late 2020. The merger strengthened the combined pipeline and talent pool for neurological and dermatological disease drug development.

Therapeutic areas: DermatologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

ALZ001

Phase 2

Indications: Acne vulgaris, Psoriasis, Keloids

2 more assets in the full pipeline.

Request access →

Partnerships

Backed by several distinguished financial institutions in Taiwan prior to merger; no specific pharma partnerships listed post-merger.

Beyond the preview

Go deeper on Allianz Pharmascience Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allianz Pharmascience Ltd.

Explore the full profile